Ana Marín‐Niebla

1.2k total citations
35 papers, 555 citations indexed

About

Ana Marín‐Niebla is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Ana Marín‐Niebla has authored 35 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pathology and Forensic Medicine, 16 papers in Oncology and 13 papers in Genetics. Recurrent topics in Ana Marín‐Niebla's work include Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (13 papers) and CAR-T cell therapy research (10 papers). Ana Marín‐Niebla is often cited by papers focused on Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (13 papers) and CAR-T cell therapy research (10 papers). Ana Marín‐Niebla collaborates with scholars based in Spain, United States and South Korea. Ana Marín‐Niebla's co-authors include Santiago R. Leal‐Noval, J. Loscertales, Ángel Herruzo-Avilés, J.L. García Garmendia, Antonio Marín-Caballos, Victoria Arellano‐Orden, María D. Rincón-Ferrari, Aurelio Cayuela, Carmen Ferrándiz‐Millón and Rosario Amaya‐Villar and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ana Marín‐Niebla

33 papers receiving 535 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ana Marín‐Niebla Spain	10	177	173	129	93	87	35	555
Ryan A. Metcalf United States	12	91 0.5×	131 0.8×	72 0.6×	70 0.8×	91 1.0×	44	460
Chaker Aloui France	11	28 0.2×	147 0.8×	32 0.2×	49 0.5×	25 0.3×	28	480
E. Wouters Belgium	8	54 0.3×	343 2.0×	63 0.5×	68 0.7×	48 0.6×	15	626
Brian C. Cho United States	14	28 0.2×	111 0.6×	158 1.2×	72 0.8×	15 0.2×	44	754
Mary F. McGuire United States	11	18 0.1×	38 0.2×	83 0.6×	51 0.5×	27 0.3×	25	454
Caroline Sut France	10	19 0.1×	137 0.8×	37 0.3×	48 0.5×	25 0.3×	15	417
M.U. Heim Germany	12	44 0.2×	65 0.4×	31 0.2×	22 0.2×	97 1.1×	28	450
Akinori Maeda Japan	11	33 0.2×	18 0.1×	105 0.8×	26 0.3×	40 0.5×	48	539
Lawrence N. Button United States	10	102 0.6×	75 0.4×	93 0.7×	23 0.2×	140 1.6×	14	621
Sofiane Tariket France	10	16 0.1×	181 1.0×	36 0.3×	67 0.7×	24 0.3×	16	425

Countries citing papers authored by Ana Marín‐Niebla

Since Specialization

Citations

This map shows the geographic impact of Ana Marín‐Niebla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Marín‐Niebla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Marín‐Niebla more than expected).

Fields of papers citing papers by Ana Marín‐Niebla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Marín‐Niebla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Marín‐Niebla. The network helps show where Ana Marín‐Niebla may publish in the future.

Co-authorship network of co-authors of Ana Marín‐Niebla

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Marín‐Niebla. A scholar is included among the top collaborators of Ana Marín‐Niebla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Marín‐Niebla. Ana Marín‐Niebla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Navarro, Vı́ctor, Moraima Jiménez, Marc Bosch, et al.. (2025). Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders. Blood Advances. 9(16). 4180–4189. 1 indexed citations

Witzig, Thomas E., Lubomir Sokol, Alejandro Martı́n, et al.. (2024). Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma. Blood Advances. 8(17). 4581–4592. 7 indexed citations

Navarro, Vı́ctor, Gloria Iacoboni, Juan‐Manuel Sancho, et al.. (2024). Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes. Haematologica. 110(1). 173–178. 1 indexed citations

Jiménez, Moraima, Alba Cabirta, Isabel Ruíz-Camps, et al.. (2023). Impact of COVID‐19 infection on bispecific antibodies treatment in patients diagnosed with B‐cell lymphoproliferative disorders. Hematological Oncology. 41(S2). 607–609. 1 indexed citations

Zinzani, Pier Luigi, Jiřı́ Mayer, Ohad Benjamini, et al.. (2023). A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B‐cell malignancies: waveLINE‐006. Hematological Oncology. 41(S2). 564–565. 2 indexed citations

Ligero, Marta, Marc Simó, Cecilia Carpio, et al.. (2023). PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma. SHILAP Revista de lepidopterología. 4(4). 1081–1088. 7 indexed citations

Zinzani, Pier Luigi, Jiří Mayer, Ohad Benjamini, et al.. (2023). waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.. Journal of Clinical Oncology. 41(16_suppl). TPS7595–TPS7595. 2 indexed citations

Kim, Won Seog, Jake Shortt, Pier Luigi Zinzani, et al.. (2023). Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL). Cancer Research. 83(8_Supplement). CT024–CT024. 12 indexed citations

Abrisqueta, Pau, Daniel Medina, Guillermo Villacampa, et al.. (2022). A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. Blood Advances. 6(21). 5763–5773. 2 indexed citations

10.

Iacoboni, Gloria, Marc Simó, Guillermo Villacampa, et al.. (2021). Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Annals of Hematology. 100(9). 2303–2310. 41 indexed citations

11.

Cabirta, Alba, Pau Abrisqueta, Sabela Bobillo, et al.. (2021). Early Relapse after First Line Has a Significant Impact on Overall Survival in Patients with Mantle Cell Lymphoma (MCL). Blood. 138(Supplement 1). 1357–1357. 2 indexed citations

12.

Witzig, Thomas E., Lubomir Sokol, Eric D. Jacobsen, et al.. (2018). Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. Blood. 132(Supplement 1). 2937–2937. 2 indexed citations

13.

Espigado, Ildefonso, et al.. (2008). High Rate of Long-Term Survival for High-Risk Lymphoma Patients Treated With Hematopoietic Stem Cell Transplantation as Consolidation or Salvage Therapy. Transplantation Proceedings. 40(9). 3104–3105. 4 indexed citations

14.

López‐Cortés, Luís F., Rosa Ruiz-Valderas, Josefa Ruiz‐Morales, et al.. (2006). Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. Journal of Antimicrobial Chemotherapy. 58(5). 1017–1023. 19 indexed citations

15.

Leal‐Noval, Santiago R., María D. Rincón-Ferrari, Ana Marín‐Niebla, et al.. (2006). Transfusion of erythrocyte concentrates produces a variable increment on cerebral oxygenation in patients with severe traumatic brain injury. Intensive Care Medicine. 32(11). 1733–1740. 81 indexed citations

16.

Espigado, Ildefonso, Ana Marín‐Niebla, Eduardo Ríos, et al.. (2005). Hemopoietic Stem Cell Transplantation in Childhood: Reduction in Mortality and Improvement of Survival Over the Years. Transplantation Proceedings. 37(3). 1555–1556. 3 indexed citations

17.

Leal‐Noval, Santiago R., et al.. (2005). Effects of a Leukocyte Depleting Arterial Line Filter on Perioperative Morbidity in Patients Undergoing Cardiac Surgery: A Controlled Randomized Trial. The Annals of Thoracic Surgery. 80(4). 1394–1400. 31 indexed citations

18.

Espigado, Ildefonso, et al.. (2004). Hemopoietic stem cell transplantation in refractory rheumatoid arthritis is not a contraindication for reconstructive surgery.. PubMed. 21(5). 643–4. 1 indexed citations

19.

Espigado, Ildefonso, Ana Marín‐Niebla, M Rovira, et al.. (2003). Phase I/II trials of autologous peripheral blood stem cell transplantation in autoimmune diseases resistant to conventional therapy: preliminary results from the Spanish experience. Transplantation Proceedings. 35(2). 742–743. 5 indexed citations

20.

Leal‐Noval, Santiago R., et al.. (2003). Influence of Erythrocyte Concentrate Storage Time on Postsurgical Morbidity in Cardiac Surgery Patients. Anesthesiology. 98(4). 815–822. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact